Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Theralase Technologies ( (TSE:TLT) ) just unveiled an update.
Theralase Technologies Inc. has successfully closed a non-brokered private placement, raising approximately $CAN 310,200 through the issuance of 1,034,002 units. The funds will be used to advance their Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research and development of Rutherrin®, and for general corporate purposes. This move is expected to strengthen the company’s operational capabilities and support its ongoing research efforts, potentially enhancing its position in the pharmaceutical industry.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules. Their primary aim is the safe and effective destruction of various cancers, bacteria, and viruses.
YTD Price Performance: -14.29%
Average Trading Volume: 108,617
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$59.47M
See more data about TLT stock on TipRanks’ Stock Analysis page.